Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure
NCT02086825Phase 3Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Oct 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rifaximin in hepatic encephalopathy (HE), sponsored by NYU Langone Health. Planned start Oct 2015; status: withdrawn.
02
Drugs
rifaximin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT02086825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02086825.